Clark added the company's Clinical and Medical Products sector will be a key growth driver, and expects to benefit from new generic pharmaceutical launches and improvements in operational performance.

FORBES: Magazine Article

Patent losses and the increased threat from generic competition are the two biggest factors impacting future performance.

FORBES: Pfizer Feeling Lipitor Loss, Outlook Still Solid

Companies can differentiate themselves on sustainability performance, but the time before an issue becomes generic is short.

FORBES: How the Sustainability Frontier Keeps Moving